NCT04179474View on ClinicalTrials.gov

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

December 23, 2019

Study Completion Date

December 23, 2019

Conditions
Migraine
Interventions
DRUG

Ubrogepant

Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].

DRUG

Erenumab

Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].

DRUG

Galcanezumab

2 SC injections of galcanezumab 120 mg \[Intervention C\].

Trial Locations (2)

53095

Spaulding, West Bend

65802

QPS, Springfield

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine | Biotech Hunter | Biotech Hunter